Affiliation:
1. Boots Pharmaceuticals Research Department, The Boots Company PLC, Nottingham, UK
Abstract
SUMMARY
Autoimmune disease in NZB/W F1 mice was treated from 23 weeks of age with the novel immunomodulator BTS 63155 and, for comparative purposes, the established immunosuppressive agent cyctosporin A. Both drugs significantly improved survival compared with untreated controls. Lupus nephritis was also significantly reduced in the drug–treated groups, and this was related to reduced glomerular deposition of IgG. Autoantibody (ANA) levels were lowered by treatment with cyclosporin A, but not by BTS 63155. This latter finding may indicate a different mode of action for the two drugs. In a long term study, neither drug effected a complete cure, as autoimmune disease recurred on withdrawal of drug treatment.
Publisher
Oxford University Press (OUP)
Subject
Immunology,Immunology and Allergy
Reference14 articles.
1. Murine models of systemic lupus erylhematosus;Theophilopoulos;Adv Immunol,1986
2. Influence of cyclophos–phamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/W mice;Hahn;Arthritis Rheum,1975
3. Murine lupus nephritis: effects of glucocorticoid on circulating and tissue–bound immunoreactants;Cavallo;Lab Invest,1983
4. Prolongation of life in NZB/NZW (F1) hybrid mice by cyclosporin A;Jones;Clin Exp Immunol,1985
5. Successful treatment of autoimmunity in (NZB.NZW) Fl mice with cyclosporin and (Nva2)–cyclosporin: 11. Reduction of glomerulonephritis;Gunn;Clin Exp Immunol,1986
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献